Shares of Pharvaris (NASDAQ:PHVS - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $18.74, but opened at $18.18. Pharvaris shares last traded at $17.89, with a volume of 36,789 shares changing hands.
Analysts Set New Price Targets
Separately, JMP Securities upped their target price on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a report on Friday.
Read Our Latest Stock Analysis on PHVS
Pharvaris Trading Down 0.7 %
The business's 50 day moving average price is $19.11 and its 200-day moving average price is $19.36. The company has a market cap of $920.30 million, a price-to-earnings ratio of -6.29 and a beta of -3.06.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Patient Square Capital LP bought a new position in shares of Pharvaris during the 3rd quarter worth about $4,488,000. State Street Corp bought a new position in shares of Pharvaris during the third quarter valued at about $1,000,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Pharvaris during the 3rd quarter valued at $906,000. Sphera Funds Management LTD. grew its stake in Pharvaris by 8.9% in the third quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company's stock worth $8,136,000 after purchasing an additional 36,027 shares during the period. Finally, Jane Street Group LLC purchased a new position in Pharvaris during the third quarter valued at $526,000.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Recommended Stories
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
